Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein.

Icon for Atypon Related Articles

Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein.

J Oncol Pharm Pract. 2018 Sep 27;:1078155218801055

Authors: Shumaker AC, Bullard HM, Churpek J, Knoebel RW

Abstract
Drug-drug interactions between digoxin and the triazole antifungal agents, mediated via various cytochrome P450 isozymes, have been described in the literature. Posaconazole is not extensively metabolized by these isozymes but is both a p-glycoprotein (P-gp) substrate and inhibitor. To our knowledge, there have been no published cases of clinically significant posaconazole-digoxin drug-drug interactions. We report an interaction between posaconazole (300 mg by mouth daily) and digoxin (0.25 mg by mouth daily, Monday through Friday) resulting in atrial fibrillation with slow ventricular response and degenerating into polymorphic ventricular tachycardia.

PMID: 30259783 [PubMed - as supplied by publisher]